Latest Breaking News On - தொடக்க மருந்து வளர்ச்சி கூட்டு - Page 1 : comparemela.com

Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments - NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers - Regulatory filing for rimegepant in Europe submitted and accepted for review by European Medicines Agency for dual-acting (acute and prevention) indication for treatment of migraine - Life-cycle management studies for CGRP-antagonist program underway, including initiation of Phase 4 study of NURTEC ODT in pediatric migraine

United statesScience parkSouth africaNew havenUnited arab emiratesYale universitySouth africanDavid spiegelSosei heptaresArtizan biosciencesBristol myers squibbMaryellen mcquadeMedison pharmaRichard flavellMike beyerKorean ministry of food